Longboard Pharmaceuticals Stock Current Valuation
| LBPH Stock | USD 59.77 0.07 0.12% |
Valuation analysis of Longboard Pharmaceuticals helps investors to measure Longboard Pharmaceuticals' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. The current Enterprise Value Over EBITDA is estimated to decrease to -2.28. The current Enterprise Value Multiple is estimated to decrease to -2.28. Fundamental drivers impacting Longboard Pharmaceuticals' valuation include:
Price Book 8.4807 | Enterprise Value 2 B | Enterprise Value Ebitda (12.30) |
Overvalued
Today
Please note that Longboard Pharmaceuticals' price fluctuation is somewhat reliable at this time. Calculation of the real value of Longboard Pharmaceuticals is based on 3 months time horizon. Increasing Longboard Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Longboard Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Longboard Stock. However, Longboard Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 59.77 | Real 31.73 | Target 17.43 | Hype 59.7 | Naive 64.3 |
The intrinsic value of Longboard Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow or dividend analysis. That value may differ from its market price, which is determined by factors such as investor sentiment, market trends, headlines, and other external factors that may influence Longboard Pharmaceuticals' stock price.
Estimating the potential upside or downside of Longboard Pharmaceuticals helps investors to forecast how Longboard stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Longboard Pharmaceuticals more accurately as focusing exclusively on Longboard Pharmaceuticals' fundamentals will not take into account other important factors: Longboard Pharmaceuticals Company Current Valuation Analysis
Longboard Pharmaceuticals' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Longboard Pharmaceuticals Current Valuation | 2.05 B |
Most of Longboard Pharmaceuticals' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Longboard Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Longboard Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for Longboard Pharmaceuticals is extremely important. It helps to project a fair market value of Longboard Stock properly, considering its historical fundamentals such as Current Valuation. Since Longboard Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Longboard Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Longboard Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
Longboard Current Valuation Historical Pattern
Today, most investors in Longboard Pharmaceuticals Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Longboard Pharmaceuticals' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current valuation growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Longboard Pharmaceuticals current valuation as a starting point in their analysis.
Longboard Pharmaceuticals Current Valuation |
| Timeline |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Longboard Pharmaceuticals has a Current Valuation of 2.05 B. This is 85.73% lower than that of the Biotechnology sector and 55.89% lower than that of the Health Care industry. The current valuation for all United States stocks is 87.67% higher than that of the company.
Longboard Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Longboard Pharmaceuticals' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Longboard Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Longboard Pharmaceuticals by comparing valuation metrics of similar companies.Longboard Pharmaceuticals is currently under evaluation in current valuation category among its peers.
Longboard Pharmaceuticals ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Longboard Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Longboard Pharmaceuticals' managers, analysts, and investors.Environmental | Governance | Social |
Longboard Fundamentals
| Return On Equity | -0.47 | ||||
| Return On Asset | -0.31 | ||||
| Current Valuation | 2.05 B | ||||
| Shares Outstanding | 34.44 M | ||||
| Shares Owned By Insiders | 1.11 % | ||||
| Shares Owned By Institutions | 98.89 % | ||||
| Number Of Shares Shorted | 1.92 M | ||||
| Price To Book | 8.48 X | ||||
| EBITDA | (56.75 M) | ||||
| Net Income | (54.42 M) | ||||
| Cash And Equivalents | 87.42 M | ||||
| Cash Per Share | 5.09 X | ||||
| Total Debt | 475 K | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 11.95 X | ||||
| Book Value Per Share | 7.05 X | ||||
| Cash Flow From Operations | (50.87 M) | ||||
| Short Ratio | 0.58 X | ||||
| Earnings Per Share | (2.25) X | ||||
| Target Price | 64.67 | ||||
| Number Of Employees | 50 | ||||
| Beta | 1.09 | ||||
| Market Capitalization | 2.33 B | ||||
| Total Asset | 50.7 M | ||||
| Retained Earnings | (140.56 M) | ||||
| Working Capital | 40.45 M | ||||
| Net Asset | 50.7 M |
About Longboard Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Longboard Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Longboard Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Longboard Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
When determining whether Longboard Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Longboard Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Longboard Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Longboard Pharmaceuticals Stock:Check out Longboard Pharmaceuticals Piotroski F Score and Longboard Pharmaceuticals Altman Z Score analysis. For more detail on how to invest in Longboard Stock please use our How to Invest in Longboard Pharmaceuticals guide.You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Longboard Pharmaceuticals. If investors know Longboard will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Longboard Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.25) | Return On Assets (0.31) | Return On Equity (0.47) |
The market value of Longboard Pharmaceuticals is measured differently than its book value, which is the value of Longboard that is recorded on the company's balance sheet. Investors also form their own opinion of Longboard Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Longboard Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Longboard Pharmaceuticals' market value can be influenced by many factors that don't directly affect Longboard Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Longboard Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Longboard Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Longboard Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.